Key Laboratory of Cell Engineering of Guizhou Province, The Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China.
Department of Spine Surgery, The Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China.
PLoS One. 2018 May 17;13(5):e0197658. doi: 10.1371/journal.pone.0197658. eCollection 2018.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) urgently requires effective treatment. Bleomycin-induced lung injury models are characterized by initial inflammation and secondary fibrosis, consistent with the pathological features of IPF. Human amniotic epithelial cells (hAECs) exhibit good differentiation potential and paracrine activity and are thus ideal for cell-based clinical therapies. The therapeutic effects of hAECs on lung fibrosis are attributed to many factors. We performed a systematic review of preclinical studies investigating the treatment of pulmonary fibrosis with hAECs to provide suggestions for their clinical use. METHODS: PubMed and EMBASE were searched for original studies describing hAEC therapy in animal bleomycin-induced pulmonary fibrosis models. After quality assessments, the number and species of experimental animals, bleomycin dose, hAEC source and dosage, time and route of administration of transplanted cells in animals, and time animals were euthanized in nine controlled preclinical studies were summarized. Ashcroft scores, lung collagen contents, inflammatory cells and cytokines were quantitatively and/or qualitatively analyzed in this review. Publication bias was also assessed. RESULTS: Each of the nine preclinical studies have unique characteristics regarding hAEC use. Ashcroft scores and lung collagen contents were decreased following hAEC transplantation in bleomycin-injured mice. Histopathology was also improved in most studies following treatment with hAECs. hAECs modulated macrophages, neutrophils, T cells, dendritic cells and the mRNA or protein levels of cytokines associated with inflammatory reactions (tumor necrosis factor-α, transforming growth factor-β, interferon-γ and interleukin) in lung tissues of bleomycin-injured mice. CONCLUSIONS: hAECs alleviate and reverse the progression of bleomycin-induced lung fibrosis in mice and may represent a new clinical treatment for IPF. hAECs exert anti-inflammatory and anti-fibrotic effects by modulating macrophage, neutrophil, T cell, dendritic cell and related cytokine levels in mice with bleomycin-induced lung fibrosis. Cell generation and the route, source and timing of hAEC transplantation all determine the therapeutic effectiveness of hAECs.
背景:特发性肺纤维化(IPF)急需有效治疗。博来霉素诱导的肺损伤模型的特点是初始炎症和继发性纤维化,与 IPF 的病理特征一致。人羊膜上皮细胞(hAEC)具有良好的分化潜能和旁分泌活性,因此是细胞基础临床治疗的理想选择。hAEC 对肺纤维化的治疗效果归因于许多因素。我们对使用 hAEC 治疗肺纤维化的临床前研究进行了系统评价,为其临床应用提供建议。
方法:在 PubMed 和 EMBASE 上搜索描述 hAEC 治疗动物博来霉素诱导的肺纤维化模型的原始研究。经过质量评估,总结了 9 项对照临床前研究中实验动物的数量和种类、博来霉素剂量、hAEC 来源和剂量、移植细胞在动物中的给药时间和途径以及动物处死时间。在本综述中,定量和/或定性分析了 Ashcroft 评分、肺胶原含量、炎症细胞和细胞因子。还评估了发表偏倚。
结果:9 项临床前研究中 hAEC 使用的特点各有不同。hAEC 移植可降低博来霉素损伤小鼠的 Ashcroft 评分和肺胶原含量。大多数研究还改善了 hAEC 治疗后的组织病理学。hAEC 调节博来霉素损伤小鼠肺组织中的巨噬细胞、中性粒细胞、T 细胞、树突状细胞以及与炎症反应相关的细胞因子(肿瘤坏死因子-α、转化生长因子-β、干扰素-γ和白细胞介素)的 mRNA 或蛋白水平。
结论:hAEC 可减轻和逆转博来霉素诱导的小鼠肺纤维化的进展,可能代表 IPF 的一种新的临床治疗方法。hAEC 通过调节博来霉素诱导的肺纤维化小鼠中巨噬细胞、中性粒细胞、T 细胞、树突状细胞和相关细胞因子的水平发挥抗炎和抗纤维化作用。hAEC 细胞的产生以及 hAEC 移植的途径、来源和时间都决定了 hAEC 的治疗效果。
Cell Transplant. 2010-11-19
Am J Respir Crit Care Med. 2010-6-3
Stem Cell Res Ther. 2015-1-29
Cell Transplant. 2012-10-4
Stem Cells Transl Med. 2018-1-3
Stem Cells Transl Med. 2016-11-7
Stem Cell Res Ther. 2017-11-28
Stem Cell Res Ther. 2020-10-15
Stem Cell Rev Rep. 2021-2
Front Pharmacol. 2020-1-23
BMC Biol. 2017-6-29
Nature. 2017-5-31
Stem Cells Transl Med. 2016-11-7
Trends Immunol. 2017-3-6
Stem Cells Int. 2016
Stem Cells Transl Med. 2015-12
Stem Cell Res Ther. 2014-9-4